HIF-1a Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR).
Song CW, Kim H, Cho H, Kim MS, Paek SH, Park HJ, Griffin RJ, Terezakis S, Cho LC. HIF-1a Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR). Cancers (Basel). 2022 Jul 04; 14(13).